Oral etoposide for kaposi’s mediterranean sarcoma

Lucia Brambilla, V. Boneschia, S. Fossati, E. Melotti, M. Clericib

Research output: Contribution to journalArticlepeer-review


22 patients affected by locally aggressive or generalized form of Kaposi’s Mediterranean sarcoma were treated with oral etoposide (VP16) as single-drug therapeutic regimen. Of the 17 evaluable patients, 10 were pretreated with other chemotherapeutic regimens. VP16 was administered at the dose of 100 mg daily for 3-5 days every 3 weeks for 3 times during induction, then every 4 weeks for 10-12 times during maintenance. Hematological (35.2%) and gastrointestinal (64.7%) toxicities were always mild and swiftly reversible. Good percentages of objective responses were achieved in both nonpretreated (85.6%) and pretreated (70%) patients. The chemotherapeutic regimen employed, the way of drug administration, the results as well as the comparison to another study withvinblastine are discussed.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
Issue number6
Publication statusPublished - 1988


  • Etoposide
  • Kaposi’s Mediterranean sarcoma
  • Systemic oral chemotherapy

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Oral etoposide for kaposi’s mediterranean sarcoma'. Together they form a unique fingerprint.

Cite this